Randomized controlled trials, or other trials with two or more arms, should list the interventions separately for each arm of the study. Drug interventions should be identified by a generic name if available; when there is not yet a generic name, the company serial number or the chemical name may be used. Devices should be described as fully as possible, using a formal nomenclature whenever appropriate (eg, Global Medical Device Nomenclature; GMDN; Radley, Oxford, UK).12 Biologics, including vaccines, should also be fully described. Although “pneumococcal vaccine” may seem specific, there can be multiple versions of such a vaccine, and it would be important to know which version is being tested. In all cases, once a marketed name is available, the records should be modified to include the marketed name (along with previous names).